Sunitinib is a kinase inhibitor targeting VEGFR-1, -2 and -3, PDGFR alpha and beta, stem-cell factor receptor (KIT), FLT3 and RET that has demonstrated antitumor activity as a single agent in phase II studies, in patients with refractory NSCLC, with RR of 2.1–11.1% [30–31]. Here, FLT1 is linked to non-small cell lung carcinoma.